Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C

Antiviral Therapy

Volumn 20, Issue 7, 2015, Pages 699-708

  Lawitz, Eric ^a   Gruener, Daniel ^b   Marbury, Thomas ^c   Hill, John ^d   Webster, Lynn ^e   Hassman, David ^f   Nguyen, Anh Hoa ^g   Pflanz, Stefan ^g   Mogalian, Erik ^g   Gaggar, Anuj ^g   Massetto, Benedetta ^g   Subramanian, G Mani ^g   McHutchison, John G ^g   Jacobson, Ira M ^h   Freilich, Bradley ⁱ   Rodriguez Torres, Maribel ^j  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b CRI Worldwide ^*  (United States)

^c ORLANDO CLINICAL RESEARCH CENTER   (United States)

^d Avail Clinical Research LLC   (United States)

^e Lifetree Clinical Research   (United States)

^f Comprehensive Clinical Research ^*  (United States)

^g GILEAD SCIENCES   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ Kansas City Gastroenterology and Hepatology   (United States)

^j Fundacion de Investigacion   (Puerto Rico)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MESSENGER RNA; PLACEBO; VESATOLIMOD; VIRUS RNA; ANTIVIRUS AGENT; BIOLOGICAL MARKER; CYTOKINE; GS-9620; ISG15 PROTEIN, HUMAN; PTERIDINE DERIVATIVE; TOLL LIKE RECEPTOR 7; UBIQUITIN;

ABDOMINAL PAIN; ADULT; AGED; ANTIVIRAL ACTIVITY; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CHOLANGITIS; CHRONIC HEPATITIS C; CONTROLLED STUDY; COUGHING; DEPRESSION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EYE JAUNDICE; FEMALE; GENE; GENE EXPRESSION; HEADACHE; HUMAN; ISG15 GENE; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; NOSE OBSTRUCTION; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; TOOTH EXTRACTION; TOOTH PAIN; ADOLESCENT; AGONISTS; CLINICAL TRIAL; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BIOMARKERS; CYTOKINES; FEMALE; GENE EXPRESSION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PTERIDINES; RNA, MESSENGER; TOLL-LIKE RECEPTOR 7; TREATMENT OUTCOME; UBIQUITINS; VIRAL LOAD; YOUNG ADULT;

EID: 84973915672     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2845     Document Type: Article

References (16)

1. Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA. Pattern recognition receptors and the innate immune response to viral infection. Viruses 2011; 3:920-940.
2. Bao M, Liu YJ. Regulation of TLR7/9 signaling in plasmacytoid dendritic cells. Protein Cell 2013; 4:40-52.
3. Heim MH. Innate immunity and HCV. J Hepatol 2013; 58:564-574.
4. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303:1529-1531.
5. Lee J, Wu CC, Lee KJ, et al. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci U S A 2006; 103:1828-1833.
6. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006; 7:131-137.
7. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008; 8:559-568.
8. Horscroft NJ, Pryde DC, Bright H. Antiviral applications of Toll-like receptor agonists. J Antimicrob Chemother 2012; 67:789-801.
9. Fosdick A, Zheng J, Pflanz S, et al. Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther 2014; 348:96-105.
10. Lopatin U, Wolfgang G, Tumas D, et al. Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist. Antivir Ther 2013; 18:409-418.
11. Ferenci P. Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future. Expert Opin Drug Saf 2011; 10:529-544.
12. Vezali E, Aghemo A, Colombo M. Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. Expert Opin Biol Ther 2011; 11:301-313.
13. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-408.
14. Bergmann JF, de Bruijne J, Hotho DM, et al. Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Aliment Pharmacol Ther 2011; 34:443-453.
15. Boonstra A, Liu BS, Groothuismink ZM, et al. Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7. Antivir Ther 2012; 17:657-667.
16. Sheridan C. FDA approvals usher in the post-interferon era in HCV. Nat Biotechnol 2014; 32:3-5.